Study details
Enrolling now
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Stanford University
NCT IDNCT06731933ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
16
Study length
about 1.9 years
Ages
18+
Locations
1 site in CA
What this study is about
This trial is testing a treatment called BVEC to see if it can help prevent Squamous Cell Carcinoma (SCC) recurrence in people with Recessive Dystrophic Epidermolysis Bullosa (RDEB). The goal is to normalize the tumor microenvironment and reduce tumor recurrence.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BVEC
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Oncology